Navigation Links
Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
Date:10/11/2007

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will release its third quarter 2007 financial results on Tuesday, October 30, 2007 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call at 4:30 p.m. ET hosted by Henry L. Nordhoff, chairman, president and chief executive officer, and Herm Rosenman, senior vice president, finance, and chief financial officer.

The conference call will be webcast live and may be accessed on the investment information section of the Company's web site at http://www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 800-947-6450 (U.S.) or 203- 369-3539. (international).

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives,
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...nsure Emergency Deliveries are Transported ,,...eamster members employed by the Philadelphia chapt...ating the public about the unfair labor conditions...delphia,s blood supply at risk. More than 100 emp...terday when their issues were ignored by their emp...
(Date:12/4/2009)..., Ill., Dec. 4 Shared Imaging, LLC...stems and service programs for hospitals and healt...eived The Joint Commission,s Accreditation for Amb...tigious gold seal of approval for quality and safe...s system-wide for its mobile MRI and PET/CT servic...
(Date:12/4/2009)...Md., Dec. 4 PharmAthene,...eloping medical countermeasures against biological...mpany is presenting results of a study demonstrati...ation anthrax model in the New Zealand White (NZW)...ral session at the HHS Public Health Emergency Med...
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 1AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 2AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 3AMDL Diagnostics Inc Enters Into Exclusive Distribution Agreement With Grifols USA LLC to Advance Commercialization of DR 70 Onko Sure 28TM 29 Canc 5327 4Help is Here Express Arrives in Anderson Seneca 5322 1Help is Here Express Arrives in Anderson Seneca 5322 2Elseviers Health Sciences Division and Peking University Medical Press cooperate on book donation 59133 1Elseviers Health Sciences Division and Peking University Medical Press cooperate on book donation 59133 2
(Date:12/4/2009)...han 15 million Americans are recruited annually to...lliance for Human Research Protection (AHRP), and ... , Research institutions view payments to vol... as compensation for potential risks related to pa...inds that volunteers have a very different view of...
(Date:12/4/2009)... exercise, water and fruit consumption leads to s... (HealthDay News) -- Increased exercise, reduced s...st effective weight control strategies for adolesc... 130 adolescents about their weight-control strate... in losing weight and 68 had not. The responses we...
(Date:12/4/2009)...nd surveillance urged for at-risk patient groups ,...me childhood cancers, particularly Ewing sarcomas ...of late recurrence, U.S. researchers have found. ,...ve-year survivors of the most common pediatric can...vivor Study. , The researchers found that the o...
(Date:12/4/2009)... knowledge of risks, many hesitate to take breast .... 4 (HealthDay News) -- Worries about side effects... women at high risk for breast cancer are willing ... a new study finds. , In an effort to inform wo...earchers at the University of Michigan Comprehensi...
(Date:12/4/2009)... , JACKSONVILLE, Fla., Dec. 4 /PRNewswire/ -...d awards for their work in improving the health of...oundation for a Healthy Florida,s 2009 Sapphire Aw...s only statewide award that recognizes and promote...in addressing health disparities within their comm...
Breaking Medicine News(10 mins):Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
...d over again, it is only tiny gadgets that have ch...orld. Researchers have developed a small device re...lp people with balance // disorder, by giving the ...isorders, a common result of ototoxicity, can affe...
...irus, named human bocavirus, that may be responsib...ildren has been identified by a group of Swedish r...nitiate a systematic // search for all the viruse...ng of viruses to help in speedy diagnosis and appr...
...tive medicine may no longer be truly alternative s... 34,000 readers. The report revealed that Chiropra...ts, including prescription drugs, // by readers wi...pain deemed acupuncture and acupressure less effec...
...hers from Mayo clinic had attributed the rising ra...oing hemodialysis to increased levels of heparin a...e August issue of Mayo Clinic Proceedings // is a ...adverse outcomes also had elevated levels of hepar...
...cessful attempts of scientists to create stem cell...addition to reprogramming to the embryonic state c...on of human embryos for the same. // If futu...technical hurdle, the hybrid cells could theoretic...
...idepressant Seroxat has been linked to increased s...sted that appropriate warning should be given to d...se effect of the drug. // The drug has alread... whom seven attempted to end their life. The resul...
Other Medicine News:
...lexible Impact And Impact2 Pipettors , , Availabl...annel Impact and Impact2 pipettors can effectively...ith the same ergonomic design and superior functio...re equally easy to program for a wide range of liq...
...omic solution and best value in high performance e... and ultra lightweight design reduce hand fatigue ... lever tip ejector , Color coding for easy volum... greater performance use Hamilton AdvanTip Low Ret...
...omic solution and best value in high performance e...n and ultra lightweight design reduce hand fatigue... lever tip ejector, Color coding for easy volume...reater performance use Hamilton AdvanTip Low Reten...
Finnpipette BioControl Single Channel, 200-1000ul
Medicine Products: